NORFENAZIN “25”® clinical trials

A multicenter randomized, controlled, single-blind, adaptive phase IV clinical trial to evaluate the efficiency and effectiveness of a pre-emptive pharmacogenetic strategy for antidepressant selection in patients with depressive disorder: The PREDICT adaptive clinical trial.

This study looks at whether using a gene test can help doctors choose the best antidepressant for people with depression, especially when other treatments haven't worked well. It compares this approach to standard care.